While tamoxifen has already shown a protective effect against the risk of breast cancer, including contralateral breast cancer, in populations with BRCA1/2 mutations [21-23, 46], the use of tamoxifen as a standard preventive treatment is limited due to its side effects. The gene discussed is BRCA1; the disease is breast carcinoma.